Clinical Overview of Peptides in 2024

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Peptides have been a cornerstone of therapeutic innovation since insulin therapy was introduced in the 1920s. Over sixty peptide-based therapies are now approved for clinical use in the United States. While these molecules have long been central to research and medical practice, public awareness of their potential has expanded significantly in recent years. Peptides are increasingly discussed in relation to oncology, metabolic health, sexual wellness, and regenerative medicine. With this heightened interest, further research funding and clinical development are expected. By 2018, more than 150 peptide compounds had entered human trials, a figure that has continued to grow.

This review summarizes recent trends in peptide science and highlights therapeutic classes of particular relevance.

Defining Peptides

Peptides are short chains of amino acids linked in a precise sequence. While naturally occurring, they can also be synthesized at laboratory and industrial scale. These molecules function as regulators of numerous physiological processes, including metabolism, immune activity, sleep, cognition, tissue repair, and aging. Their biological significance stems from their role in cellular signaling and communication across multiple systems.

Research Progress and Development

Peptide drug development has advanced beyond attempts to replicate naturally occurring peptides. Current strategies often focus on designing novel synthetic structures that can act on specific receptors, even when they differ structurally from endogenous peptides.

Although the average development cycle for a peptide is approximately nine years, many compounds undergo multiple iterations. Molecules initially considered unsuitable are sometimes modified or repurposed, leading to renewed therapeutic potential. Increasingly sophisticated delivery methods are addressing challenges related to stability, storage, and administration.

Neurocognitive Applications

Peptides targeting the central nervous system can be grouped into two categories: those aimed at restoring impaired function and those intended to enhance normal performance. In practice, many exhibit overlapping properties.

• Semax and Selank, first developed in Russia, are among the earliest studied nootropic peptides. Selank influences GABAergic activity and regulates gene expression associated with learning and anxiety reduction. Semax enhances brain-derived neurotrophic factor (BDNF), supporting both neuroprotection and cognitive resilience.
• Additional compounds under investigation include BPC 157, Cerebrolysin, Pinealon, Epitalon, and P21. These agents demonstrate diverse mechanisms of action, offering insights into neuroplasticity and cognition.

Tissue Repair and Regeneration

Several peptides facilitate recovery from injury by modulating angiogenesis, fibroblast activity, and extracellular matrix synthesis.

• BPC 157 has been widely studied for its ability to accelerate tissue repair, promote vascular growth, and support gastrointestinal healing.
• TB-500 (a fragment of Thymosin Beta 4) and Mechano-Growth Factor (MGF) also demonstrate regenerative properties in musculoskeletal and connective tissues.
• GHK-Cu, a naturally occurring copper-binding peptide, exhibits anti-inflammatory and antioxidant properties, supporting dermal health and repair processes.

Healthy Aging and Longevity

Peptides have been instrumental in demonstrating that aspects of aging can be influenced by molecular signaling pathways.

• Sermorelin, a growth hormone–releasing hormone analog, has been studied for its role in counteracting age-associated decline in growth hormone levels (somatopause). Benefits include improvements in cardiac remodeling, renal function, cognitive decline, and sleep quality.

Muscle and Skeletal Support

Anabolic peptides typically act through growth hormone pathways or by inhibiting catabolic signals.

• CJC 1295 enhances growth hormone release significantly by mimicking endogenous releasing hormone.
• GHRP-2, GHRP-6, and Ipamorelin stimulate growth hormone via the ghrelin receptor. Ipamorelin is notable for its receptor selectivity and positive effects on bone integrity.
• Follistatin neutralizes myostatin, a regulator of muscle breakdown, resulting in measurable increases in muscle mass in clinical models.

Sexual Function

Sexual response is regulated by central pathways, including the melanocortin system. Peptides that act on this system demonstrate effects on arousal and broader behavioral regulation.

• Melanotan I and II and PT-141 have shown efficacy in enhancing sexual function in both men and women. They are also being evaluated for roles in appetite regulation, addictive behaviors, and skin pigmentation disorders.

Metabolic Regulation and Weight Management

Energy balance is strongly influenced by peptide-mediated pathways, and targeted interventions are under active development.

• Adipotide disrupts the blood supply to adipocytes, promoting fat loss and reducing appetite.
• AOD9604, derived from growth hormone fragments, stimulates fat metabolism with significant reductions in adiposity observed in preclinical studies.
• Tesamorelin, approved for HIV-associated lipodystrophy, reduces visceral fat accumulation while improving lipid metabolism.

Conclusion

Peptide research continues to evolve rapidly, supported by advances in molecular design and drug delivery technologies. Their clinical potential spans neurology, endocrinology, regenerative medicine, metabolic health, and beyond. While challenges remain in optimization and regulatory approval, the trajectory of peptide-based therapeutics suggests expanding applications in both treatment and health maintenance.

REFERENCES

1. Therapeutic peptides: Historical perspectives, current development trends, and future directions
2. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–2707. doi:10.1016/j.bmc.2017.06.052
3. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122–128. doi:10.1016/j.drudis.2014.10.003
4. Sevostianov A, Radchenko V, Ashmarin I, Andreeva L. Semax and Selank: synthetic analogs of regulatory peptides. Neurochem J. 2010;4(3):171–180. doi:10.1134/S1819712410030031
5. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2011;17(16):1612–1632. doi:10.2174/138161211796196924
6. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic Transl Sci. 2012;3(1):69–89. doi:10.1016/j.tcm.2012.01.002
7. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
8. Walker RF, Romsos DR. Clinical use of growth hormone releasing hormone analogues such as Sermorelin. Endocrine. 2013;43(1):27–36. doi:10.1007/s12020-012-9768-1
9. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA. 2004;101(13):4679–4684. doi:10.1073/pnas.0305930101
10. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA. 2001;98(16):9306–9311. doi:10.1073/pnas.151270098
11. Wessells H, Fuciarelli K, Hansen J, et al. Effect of the melanocortin receptor agonist PT-141 on penile erection in men with erectile dysfunction. J Urol. 2004;172(2):624–628. doi:10.1097/01.ju.0000132390.20203.bf
12. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625–632. doi:10.1038/nm1048
13. Ng FM, Turner JG, Boura AL, et al. AOD9604, a novel analog of human growth hormone, reduces body fat in obese subjects. Int J Obes (Lond). 2006;30(2):294–302. doi:10.1038/sj.ijo.0803130
14. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. doi:10.1056/NEJMoa072702